CITTRU

Cittru is a biotechnology company focused on developing first-in-class small molecule therapeutics that target undruggable proteins, specifically protein phosphatases. The company's primary focus is on the activation of Protein Phosphatase 2A (PP2A), a master regulator of cell signaling that is frequently inactivated in cancer and neurodegenerative diseases. By restoring PP2A activity, Cittru aims to provide new treatment options for patients with difficult-to-treat conditions such as KRAS-mutant cancers and Alzheimer's disease. The company leverages a proprietary platform to identify and optimize small molecule activators of these critical enzymes. Cittru's approach represents a paradigm shift from traditional inhibitor-based drug discovery by focusing on the restoration of tumor-suppressive and homeostatic functions.